Spineart, a global medtech innovator, which opened an innovation center in Dallas in 2024, recently announced a CHF (Swiss franc) 25 million capital increase. This new funding will fuel Spineart’s next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint in delivering better outcomes for spine surgery patients.
“This investment represents a major milestone in Spineart’s profitable growth journey,” said Jerome Trividic, CEO of Spineart. “Over the past years, we’ve made targeted strategic investments in product innovation, robotics, regulatory expansion in Europe and the United States and manufacturing, that are now coming to fruition.”
